Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Other Accumulated Expenses (2021 - 2026)

Champions Oncology has reported Other Accumulated Expenses over the past 6 years, most recently at $78000.0 for Q1 2026.

  • Quarterly results put Other Accumulated Expenses at $78000.0 for Q1 2026, down 49.35% from a year ago — trailing twelve months through Jan 2026 was $78000.0 (down 49.35% YoY), and the annual figure for FY2025 was $135000.0, down 10.0%.
  • Other Accumulated Expenses for Q1 2026 was $78000.0 at Champions Oncology, down from $97000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for CSBR hit a ceiling of $154000.0 in Q1 2025 and a floor of $15000.0 in Q1 2022.
  • Median Other Accumulated Expenses over the past 5 years was $144000.0 (2023), compared with a mean of $125647.1.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 860.0% in 2023 and later tumbled 49.35% in 2026.
  • Champions Oncology's Other Accumulated Expenses stood at $143000.0 in 2022, then increased by 3.5% to $148000.0 in 2023, then increased by 2.03% to $151000.0 in 2024, then crashed by 35.76% to $97000.0 in 2025, then decreased by 19.59% to $78000.0 in 2026.
  • The last three reported values for Other Accumulated Expenses were $78000.0 (Q1 2026), $97000.0 (Q4 2025), and $116000.0 (Q3 2025) per Business Quant data.